Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May;13(5):309-19.
doi: 10.1111/j.1477-2574.2010.00286.x. Epub 2011 Mar 10.

Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma

Siobhan C McKay  1 , Kristian Unger, Stephanos Pericleous, Gordon Stamp, Gerry Thomas, Robert R Hutchins, Duncan R C Spalding
Affiliations

Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma

Siobhan C McKay et al. HPB (Oxford). 2011 May.

Abstract

Background: Cholangiocarcinoma (CC) is a rare tumour with a dismal prognosis. As conventional medical management offers minimal survival benefit, surgery currently represents the only chance of cure. We evaluated DNA copy number (CN) alterations in CC to identify novel therapeutic targets.

Methods: DNA was extracted from 32 CC samples. Bacterial artificial chromosome (BAC) array comparative genomic hybridization was performed using microarray slides containing 3400 BAC clones covering the whole human genome at distances of 1 Mb. Data were analysed within the R statistical environment.

Results: DNA CN gains (89 regions) occurred more frequently than DNA CN losses (55 regions). Six regions of gain were identified in all cases on chromosomes 16, 17, 19 and 22. Twenty regions were frequently gained on chromosomes 1, 5, 7, 9, 11, 12, 16, 17, 19, 20 and 21. The BAC clones covering ERBB2, MEK2 and PDGFB genes were gained in all cases. Regions covering MTOR, VEGFR 3, PDGFA, RAF1, VEGFA and EGFR genes were frequently gained.

Conclusions: We identified CN gains in the region of 11 useful molecular targets. Findings of variable gains in some regions in this and other studies support the argument for molecular stratification before treatment for CC so that treatment can be tailored to the individual patient.

PubMed Disclaimer

Figures

Figure 1
Figure 1
DNA copy number (CN) alterations in all cases showing regions of gain and loss
Figure 2
Figure 2
ErbB2 expression using immunohistochemistry
Figure 3
Figure 3
ErbB2 expression using immunohistochemistry
Figure 4
Figure 4
Copy number (CN) gain of molecular targets in other comparative genomic hybridization studies
See this image and copyright information in PMC

References

    1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125. - PubMed
    1. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–1357. - PubMed
    1. West J, Wood H, Logan RFA, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006;94:1751–1758. - PMC - PubMed
    1. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–813. - PubMed
    1. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. [Review.] Cancer. 1995;75:171–190. - PubMed

MeSH terms